Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesar A Arias

Showing results (171-180 of 309) with videos related to

Pageof 31
Sort By:
Jac-Antimicrobial Resistance|July 5, 2021
Selective digestive decontamination with oral colistin plus gentamicin for persistent bacteraemia caused by non-carbapenemase-producing carbapenem-resistant <i>Klebsiella pneumoniae</i> in a neutropenic patientMaria Spencer-Sandino, Roberto Riquelme-Neira, William C Shropshire, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2020
Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin SusceptibilitiesTaylor Morrisette, Katherine L Lev, Razieh Kebriaei, et al.
Case Reports in Infectious Diseases|October 1, 2019
Corrigendum to "<i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated Pathways"Erik Skoglund, Henrietta Abodakpi, Rafael Rios, et al.
The Journal of Infectious Diseases|November 27, 2024
Comprehensive Assessment of Initial Adaptation of Extended-Spectrum β-Lactamase-Positive ST131 Escherichia coli to Carbapenem ExposureWilliam C Shropshire, Xinhao Song, Jordan Bremer, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Comprehensive Assessment of Initial Adaptation of ESBL Positive ST131 <i>Escherichia coli</i> to Carbapenem ExposureWilliam C Shropshire, Xinhao Song, Jordan Bremer, et al.
Case Reports in Infectious Diseases|January 25, 2019
<i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated PathwaysErik Skoglund, Henrietta Abodakpi, Rafael Rios, et al.
Msystems|June 26, 2023
Identification of distinct impacts of CovS inactivation on the transcriptome of acapsular group A streptococciSruti DebRoy, William C Shropshire, Luis Vega, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2021
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosaLina Rivas, Manuel Alcalde-Rico, José R W Martínez, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2024
In-patient evolution of a high-persister <i>Escherichia coli</i> strain with reduced in vivo antibiotic susceptibilityJoshua B Parsons, Ashelyn E Sidders, Amanda Z Velez, et al.
Open Forum Infectious Diseases|July 9, 2019
Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United StatesAyesha Khan, Truc T Tran, Rafael Rios, et al.
Pageof 31

Showing results (171-180 of 309) with videos related to

Sort By:
Pageof 31
Jac-Antimicrobial Resistance|July 5, 2021
Selective digestive decontamination with oral colistin plus gentamicin for persistent bacteraemia caused by non-carbapenemase-producing carbapenem-resistant <i>Klebsiella pneumoniae</i> in a neutropenic patientMaria Spencer-Sandino, Roberto Riquelme-Neira, William C Shropshire, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2020
Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin SusceptibilitiesTaylor Morrisette, Katherine L Lev, Razieh Kebriaei, et al.
Case Reports in Infectious Diseases|October 1, 2019
Corrigendum to "<i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated Pathways"Erik Skoglund, Henrietta Abodakpi, Rafael Rios, et al.
The Journal of Infectious Diseases|November 27, 2024
Comprehensive Assessment of Initial Adaptation of Extended-Spectrum β-Lactamase-Positive ST131 Escherichia coli to Carbapenem ExposureWilliam C Shropshire, Xinhao Song, Jordan Bremer, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Comprehensive Assessment of Initial Adaptation of ESBL Positive ST131 <i>Escherichia coli</i> to Carbapenem ExposureWilliam C Shropshire, Xinhao Song, Jordan Bremer, et al.
Case Reports in Infectious Diseases|January 25, 2019
<i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated PathwaysErik Skoglund, Henrietta Abodakpi, Rafael Rios, et al.
Msystems|June 26, 2023
Identification of distinct impacts of CovS inactivation on the transcriptome of acapsular group A streptococciSruti DebRoy, William C Shropshire, Luis Vega, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2021
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosaLina Rivas, Manuel Alcalde-Rico, José R W Martínez, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2024
In-patient evolution of a high-persister <i>Escherichia coli</i> strain with reduced in vivo antibiotic susceptibilityJoshua B Parsons, Ashelyn E Sidders, Amanda Z Velez, et al.
Open Forum Infectious Diseases|July 9, 2019
Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United StatesAyesha Khan, Truc T Tran, Rafael Rios, et al.
Pageof 31